Four uses have real clinical data. The rest don't. The strongest is antibiotic-associated diarrhea: the right strain alongside a course cut C. difficile diarrhea by about 60% 1, with the benefit living in S. boulardii and L. rhamnosus GG 2. For recurrent bacterial vaginosis, prescription Lactin-V (L. crispatus CTV-05) after antibiotics cut 12-week recurrence from 45% to 30% 3. For infant eczema in atopic families, L. rhamnosus GG in late pregnancy and to the baby halves the risk by age two 4. And B. infantis 35624 eases IBS bloating in about one in seven 5. A generic blend delivers none of these.
They're a tool you use, not a thing you install. The picture most people have, a capsule "reseeding" your gut so good bacteria stick around, mostly doesn't happen. Biopsies of people taking an 11-strain blend found the strains in about half; the rest were resistant, decided by their existing microbes rather than the dose 6. Stop, and the visitors clear within weeks. Probiotics work while you take them.
Everything turns on matching the strain to the problem. Mismatch is the cleanest way to waste money in the category.
Check the label for a CFU count at end of shelf life, not "at manufacture." The second wording lets a product decay to nothing by the date you swallow it.
When you match it right, the win is what doesn't happen. A week into S. boulardii with an antibiotic, the course ends and your gut settles within a day of the last pill instead of ruining the week after. Three months after Lactin-V, the every-few-months BV pattern stops and you lose count of the weeks since. Fermented foods pay off slowest: the inflammatory blood markers that drift up with age start trending back down 7, which you never feel but your fifty-year-old numbers will.
The fine print — when to skip it, and what people get wrong
"Take a probiotic after antibiotics to restore your gut." Worse than nothing: it delayed the gut's own recovery by months, while doing nothing recovered in weeks 8. Take it during the course, then stop.
A few people shouldn't take them. The harm is the live organism reaching the blood: skip routine probiotics with a central line, severe immunodeficiency, short bowel, endocarditis-risk heart disease, or critical ICU illness. Healthy pregnancy is fine.
- 1Goldenberg JZ, Yap C, Lytvyn L, et al. (2017). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews. link
- 2McFarland LV, Evans CT, Goldstein EJC (2018). Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Frontiers in Medicine. link
- 3Cohen CR, Wierzbicki MR, French AL, et al. (2020). Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. New England Journal of Medicine. link
- 4Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E (2001). Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. The Lancet. link
- 5Whorwell PJ, Altringer L, Morel J, et al. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. American Journal of Gastroenterology. link
- 6Zmora N, Zilberman-Schapira G, Suez J, et al. (2018). Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell. link
- 7Wastyk HC, Fragiadakis GK, Perelman D, et al. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell. link
- 8Suez J, Zmora N, Zilberman-Schapira G, et al. (2018). Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell. link
დაკავშირებული სახელმძღვანელოში (8)
- — A few specific strains genuinely ease IBS bloating and pain — but it's strain-specific, not the broad-spectrum capsule on the shelf.
- — The best-evidenced use: a specific strain, S. boulardii, taken during an antibiotic course to prevent diarrhea.
- — If you want the immune-quieting benefit without buying capsules, fermented foods are the cheaper route.
- — FMT is the industrial-strength version of the reseed-the-gut idea that probiotics gesture at.
- — The mood claims ride on the gut-brain axis — a few strains show real signal, most of the shelf is hope.
- — For recurrent C. diff, off-the-shelf probiotics fall short; the approved live biotherapeutics are what re-seed the gut.
- — The same vaginal-lactobacilli logic behind treating bacterial vaginosis is used to defend against repeat UTIs — strain-specific again.
- — The label tells you little — strain identity and a third-party seal are what separate real from placebo.
Probiotics
$0.20–$1.50/day for evidence-graded supplement strains (S. boulardii CNCM I-745, L. rhamnosus GG, B. infantis 35624) — well under $500/year even at upper end. Lactin-V and live biotherapeutics are pricier but typically time-limited courses. Fermented-food approach is roughly the cost of a daily yogurt habit.
Taking a capsule once or twice daily during an antibiotic course or a defined intervention period is trivial; fermented-food intake is a routine dietary adjustment. Sustained daily compliance over months for IBS or atopy-prevention indications adds modest friction but no lifestyle reorganization.
Strain-matched indication-specific gains are real and felt within weeks: ~60% RR reduction in C. difficile-associated diarrhea during antibiotic courses with S. boulardii or L. rhamnosus GG (Goldenberg 2017; Szajewska 2015); ~15-point absolute reduction in BV recurrence at 12 weeks with Lactin-V (Cohen 2020); B. infantis 35624 measurably improves IBS pain/bloating at 4 weeks (Whorwell 2006).
Bimodal across indications. AAD/CDI prevention with named strains is moderate-certainty Cochrane evidence (39 RCTs, RR 0.40 for CDAD; Goldenberg 2017) and AGA conditionally recommended (Su 2020). Lactin-V is NEJM phase-2b positive (Cohen 2020). Infant eczema prevention in atopic families is multi-trial replicated (Kalliomäki 2001; Wickens 2008; WAO 2015). IBS, generic adult wellness, and IBD signals are weak. The largest single AAD RCT was negative (PLACIDE; Allen 2013), explained by strain choice but legitimately tempers the field. Overall: small-and-preliminary-to-good for the specific indications, no real evidence for generic use.
Indirect, modest: infant L. rhamnosus GG / HN001 prevention of eczema halves cumulative incidence by 2 years (Kalliomäki 2001; Wickens 2008); a fermented-food diet lowers systemic inflammatory markers including IL-6 (Wastyk 2021), which over months plausibly contributes to skin quality. No appearance-targeted RCTs in adults.
No direct mortality data. The Wastyk fermented-food trial documents reductions in 19 inflammatory proteins including IL-6 — a marker mechanistically linked to chronic-disease risk — over 10 weeks (Wastyk 2021), supporting a small additive plausibility. CDI prevention during high-risk antibiotic courses prevents a small number of CDI-attributable deaths at population scale (Goldenberg 2017).
Indirect: reduced abdominal pain and bloating in IBS responders to B. infantis 35624 plausibly improves day-to-day mood (Whorwell 2006). Direct psychobiotic claims for depression/anxiety are not yet supported at indication-grade trial quality and the AGA does not endorse them (Su 2020).